Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122886002 | 12288600 | 2 | F | 20160913 | 20160421 | 20160915 | EXP | CA-ROCHE-1743788 | ROCHE | 46.00 | YR | F | Y | 0.00000 | 20160915 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122886002 | 12288600 | 1 | PS | CAPECITABINE. | CAPECITABINE | 1 | Unknown | U | 20896 | 800 | MG | TABLET | BID | ||||||
| 122886002 | 12288600 | 2 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | THERAPY DURATION: 2 YEARS | U | 0 | 10 | MG | TABLET | QD | |||||
| 122886002 | 12288600 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | U | 0 | 60 | MG | QOW | |||||||
| 122886002 | 12288600 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | U | 0 | 30 | MG | QOW | |||||||
| 122886002 | 12288600 | 5 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Unknown | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122886002 | 12288600 | 1 | Product used for unknown indication |
| 122886002 | 12288600 | 2 | Neuroendocrine tumour |
| 122886002 | 12288600 | 3 | Neuroendocrine tumour |
| 122886002 | 12288600 | 5 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122886002 | 12288600 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122886002 | 12288600 | Abdominal distension | |
| 122886002 | 12288600 | Alopecia | |
| 122886002 | 12288600 | Ascites | |
| 122886002 | 12288600 | Asthenia | |
| 122886002 | 12288600 | Blood glucose decreased | |
| 122886002 | 12288600 | Blood pressure decreased | |
| 122886002 | 12288600 | Cough | |
| 122886002 | 12288600 | Decreased appetite | |
| 122886002 | 12288600 | Diarrhoea | |
| 122886002 | 12288600 | Fatigue | |
| 122886002 | 12288600 | General physical health deterioration | |
| 122886002 | 12288600 | Haemoglobin decreased | |
| 122886002 | 12288600 | Hypersomnia | |
| 122886002 | 12288600 | Inappropriate schedule of drug administration | |
| 122886002 | 12288600 | Malignant neoplasm progression | |
| 122886002 | 12288600 | Musculoskeletal pain | |
| 122886002 | 12288600 | Neck pain | |
| 122886002 | 12288600 | Neoplasm | |
| 122886002 | 12288600 | Night sweats | |
| 122886002 | 12288600 | Poor quality sleep | |
| 122886002 | 12288600 | Pyrexia | |
| 122886002 | 12288600 | Respiratory rate increased | |
| 122886002 | 12288600 | Tearfulness | |
| 122886002 | 12288600 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |